welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy
study id #: NCT02034305
condition: Duchenne Muscular Dystrophy
This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP, SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.
mechanism of action: No pharmaceutical intervention
last updated: February 15, 2019
start date: January 2014
estimated completion: January 2020
size / enrollment: 15
- Spontaneous cough clearance [ Time Frame: Assessed at multiple time points over 30 minutes ]
• Age 6-21; able to cooperate with study procedures
• Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy
• Need for mechanical ventilation during the day
• Recent (within 2 weeks) lower respiratory tract infection
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pati...
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...